På Placera och Avanza använder vi cookies för att säkerställa funktionalitet, personalisera innehåll och annonser och för att analysera hur sajten används. Genom att godkänna accepterar du att cookies används. Läs mer och hantera inställningar

Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19

Senaste inlägg
Rubrik Av Publicerat
Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19 Tisson 20-05-12 21:51
1/1
Gilead Sciences / Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19 / Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19
2020-05-12 21:51 IP: Q2/fqr0MK
https://www.equitybulls.com/admin/news2006/news_det.asp?id=266203

Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited ("Jubilant"), has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that will grant Jubilant the right to register, manufacture and sell Gilead"s investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India. These countries consist of nearly all low-income and lower middle-income countries, as well as several uppermiddle and high-income countries that face significant obstacles to healthcare access. Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by regulatory authorities in respective countries.


Patrik

Har du synpunkter eller åsikter om forumet? Vänligen kontakta oss på forum@placera.nu.

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
- -
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Olja - -
Guld - -
Silver - -
Koppar - -